407 related articles for article (PubMed ID: 26562136)
1. [Effectiveness of Intravitreal Aflibercept Injections in Patients who had Received 10 and More Ranibizumab Injections in Advance].
Lenk J; Matthé E; Pillunat LE; Sandner D
Klin Monbl Augenheilkd; 2016 Mar; 232(3):284-9. PubMed ID: 26562136
[TBL] [Abstract][Full Text] [Related]
2. Functional and anatomic efficacy of a conversion to aflibercept in eyes with age-related macular degeneration after long-term ranibizumab treatment.
Gerding H
Klin Monbl Augenheilkd; 2015 Apr; 232(4):560-3. PubMed ID: 25902122
[TBL] [Abstract][Full Text] [Related]
3. Neovascular age-related macular degeneration treated with ranibizumab or aflibercept in the same large clinical setting: visual outcome and number of injections.
Rasmussen A; Sander B; Larsen M; Brandi S; Fuchs J; Hansen LH; Lund-Andersen H
Acta Ophthalmol; 2017 Mar; 95(2):128-132. PubMed ID: 27535819
[TBL] [Abstract][Full Text] [Related]
4. Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration.
Barthelmes D; Campain A; Nguyen P; Arnold JJ; McAllister IL; Simpson JM; Hunyor AP; Guymer R; Essex RW; Morlet N; Gillies MC;
Br J Ophthalmol; 2016 Dec; 100(12):1640-1645. PubMed ID: 26994110
[TBL] [Abstract][Full Text] [Related]
5. Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD.
Batioglu F; Demirel S; Özmert E; Abdullayev A; Bilici S
BMC Ophthalmol; 2015 Apr; 15():40. PubMed ID: 25885684
[TBL] [Abstract][Full Text] [Related]
6. Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD.
Waizel M; Todorova MG; Masyk M; Wolf K; Rickmann A; Helaiwa K; Blanke BR; Szurman P
BMC Ophthalmol; 2017 May; 17(1):79. PubMed ID: 28535756
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of Functional and Morphological Outcome after Aflibercept or Ranibizumab in Chronic Recurrent Neovascular Age-Related Macular Degeneration].
Hoffmann AE; Maier M; Lohmann CP; Feucht N
Klin Monbl Augenheilkd; 2016 Nov; 233(11):1260-1265. PubMed ID: 27130974
[No Abstract] [Full Text] [Related]
8. Choroidal Thickness Changes After Intravitreal Antivascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration: Ranibizumab Versus Aflibercept.
Gharbiya M; Cruciani F; Mariotti C; Grandinetti F; Marenco M; Cacace V
J Ocul Pharmacol Ther; 2015; 31(6):357-62. PubMed ID: 26133059
[TBL] [Abstract][Full Text] [Related]
9. Clinical experience of switching anti-VEGF therapy from ranibizumab to aflibercept in age-related choroidal neovascularization.
Van Lancker L; Petrarca R; Moutsouris K; Masaoutis P; Kampougeris G
Eur J Ophthalmol; 2017 May; 27(3):342-345. PubMed ID: 27739561
[TBL] [Abstract][Full Text] [Related]
10. Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration.
Yun C; Oh J; Ahn J; Hwang SY; Lee B; Kim SW; Huh K
Graefes Arch Clin Exp Ophthalmol; 2016 Sep; 254(9):1693-702. PubMed ID: 26781585
[TBL] [Abstract][Full Text] [Related]
11. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
Gillies MC; Nguyen V; Daien V; Arnold JJ; Morlet N; Barthelmes D
Ophthalmology; 2016 Dec; 123(12):2545-2553. PubMed ID: 27707549
[TBL] [Abstract][Full Text] [Related]
12. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
Moon DRC; Lee DK; Kim SH; You YS; Kwon OW
Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506
[TBL] [Abstract][Full Text] [Related]
13. Short-term choroidal thickness changes in patients treated with either ranibizumab or aflibercept: a comparative study.
Kim JH; Lee TG; Chang YS; Kim CG; Cho SW
Br J Ophthalmol; 2016 Dec; 100(12):1634-1639. PubMed ID: 26951770
[TBL] [Abstract][Full Text] [Related]
14. Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice.
Despreaux R; Cohen SY; Semoun O; Zambrowski O; Jung C; Oubraham H; Souied EH
Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):639-44. PubMed ID: 26092633
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment of exudative age-related macular degeneration.
Massamba N; Dirani A; Butel N; Fardeau C; Bodaghi B; Ingram A; Lehoang P
Graefes Arch Clin Exp Ophthalmol; 2017 Jan; 255(1):61-67. PubMed ID: 27397583
[TBL] [Abstract][Full Text] [Related]
16. The effect of switching ranibizumab to aflibercept in refractory cases of macular edema secondary to ischemic central vein occlusion.
Lehmann-Clarke L; Dirani A; Mantel I; Ambresin A
Klin Monbl Augenheilkd; 2015 Apr; 232(4):552-5. PubMed ID: 25902119
[TBL] [Abstract][Full Text] [Related]
17. Short-term effect of aflibercept on visual acuity and central macular thickness in patients not responding to ranibizumab and bevacizumab.
Maksys S; Richter-Müksch S; Weingessel B; Vécsei-Marlovits PV
Wien Klin Wochenschr; 2017 May; 129(9-10):351-357. PubMed ID: 27550436
[TBL] [Abstract][Full Text] [Related]
18. Twelve-month outcomes of treatment using ranibizumab or aflibercept for neovascular age-related macular degeneration: a comparative study.
Kim JH; Lee DW; Chang YS; Kim JW; Kim CG
Graefes Arch Clin Exp Ophthalmol; 2016 Nov; 254(11):2101-2109. PubMed ID: 27230919
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab.
Narayan DS; Muecke J
Indian J Ophthalmol; 2015 Nov; 63(11):832-6. PubMed ID: 26669334
[TBL] [Abstract][Full Text] [Related]
20. Change in choroidal thickness after intravitreal injection for treatment of neovascular age-related macular degeneration: Ranibizumab versus aflibercept.
Kaya F
J Fr Ophtalmol; 2017 Dec; 40(10):832-838. PubMed ID: 29113742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]